PT-141 (10mg)

Additional Info

Properties

PT-141 Chemical Formula: C50H68N14O10

PT-141 Molecular Weight: 1025.2 g/mol

PT-141 Sequence: Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)-OH

Total Amount of the Active Ingredient: 10mg (1 vial)

Shelf Life: 36 months

Shipping

USA

Canada

If your shipment was seized (International Orders), we will provide a 50% discount applicable on your next purchase. Please contact us for more information.

Disclaimer

The information above does not substitute medical advice, diagnosis, or treatment. Should you have any questions regarding a medical condition, seek the advice of your physician or a qualified healthcare provider. Medical advice should never be disregarded or delayed because of what you have read or seen. We bear no responsibility or liability for your use of any of our research compounds and products. Please note that they are being sold for research purposes ONLY. We do NOT condone any personal use.

Additional Label & Product Information

1. Essential warning:

• The chemicals contained are only for research or laboratory use. Not approved by the FDA for human consumption.

2. Using instructions:

• Avoid skin and eye contact. If contact occurs, wash immediately with plenty of water.
• Seek medical advice if you feel unwell or in case of accidental ingestion.
• Store the lyophilised (freeze-dried) peptide at room temperature immediately upon receipt.
• Avoid frequent freeze-thaw cycles to ensure peptide stability.

3. Product Disclaimer

• This product is not intended to diagnose, treat, cure, or prevent any disease.
• Apply only as dictated by the specific research or your laboratory protocol.

Resources

1. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004 Apr;16(2):135-42. doi: 10.1038/sj.ijir.3901200. PMID: 14999221.
2. Rössler AS, Pfaus JG, Kia HK, Bernabé J, Alexandre L, Giuliano F. The melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat. Pharmacol Biochem Behav. 2006 Nov;85(3):514-21. doi: 10.1016/j.pbb.2006.09.023. Epub 2006 Nov 20. PMID: 17113634.
3. Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016 Jun;12(3):325-37. doi: 10.2217/whe-2016-0018. Epub 2016 May 16. PMID: 27181790; PMCID: PMC5384512.
4. Miller MK, Smith JR, Norman JJ, Clayton AH. Expert opinion on existing and developing drugs to treat female sexual dysfunction. Expert Opin Emerg Drugs. 2018 Sep;23(3):223-230. doi: 10.1080/14728214.2018.1527901. Epub 2018 Oct 11. PMID: 30251897.
5. Ji HX, Zou YL, Duan JJ, Jia ZR, Li XJ, Wang Z, Li L, Li YW, Liu GY, Tong MQ, Li XY, Zhang GH, Dai XR, He L, Li ZY, Cao C, Yang Y. The synthetic melanocortin (CKPV)2 exerts anti-fungal and anti-inflammatory effects against Candida albicans vaginitis via inducing macrophage M2 polarization. PLoS One. 2013;8(2):e56004. doi: 10.1371/journal.pone.0056004. Epub 2013 Feb 14. PMID: 23457491; PMCID: PMC3573073.
6. Maresca V, Flori E, Picardo M. Skin phototype: a new perspective. Pigment Cell Melanoma Res. 2015 Jul;28(4):378-89. doi: 10.1111/pcmr.12365. Epub 2015 Apr 11. PMID: 25786343.
7. Feller L, Khammissa RAG, Kramer B, Altini M, Lemmer J. Basal cell carcinoma, squamous cell carcinoma and melanoma of the head and face. Head Face Med. 2016 Feb 5;12:11. doi: 10.1186/s13005-016-0106-0. PMID: 26850723; PMCID: PMC4744388.